No Data
No Data
No Data
No Data
No Data
ALX Oncology Holdings (NASDAQ:ALXO) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it seems
Simply Wall StMay 4 08:39 ET
ALX Oncology Board Reshuffles Following Director Resignations
TipRanksMay 2 16:26 ET
Express News | ALX Oncology Announces Initiation Of Phase 2 Investigator-Sponsored Trial Of Neoadjuvant RadiationAand Evorpacept In Combination With Pembrolizumab In Patients With Untreated HPV-Mediated Oropharyngeal Cancer
BenzingaApr 30 09:12 ET
Express News | ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination With Pembrolizumab in Patients With Untreated Hpv-Mediated Oropharyngeal Cancer
ReutersApr 30 09:00 ET
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune
GlobeNewswireApr 24 10:00 ET
ALX Oncology(ALXO.US) Officer Sells US$710.2K in Common Stock
$ALX Oncology(ALXO.US)$ Officer Pons Jaume sold 50,000 shares of common stock on Apr 16, 2024 at an average price of $14.2039 for a total value of $710.2K.Source: Announcement What is statement of cha
moomoo NewsApr 18 17:31 ET
lightfoot : junk, hook, line and sinker
Clueless Noob : great post. thank you for sharing
Christopher Flint197 : like to learn what a swing trade looks like and when to get in and out.
No Data
No Data